BPMC Blueprint Medicines Corp
Price (delayed)
$81.68
Market cap
$5.22B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.07
Enterprise value
$5.58B
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company
Highlights
BPMC's gross profit has surged by 107% year-on-year and by 16% since the previous quarter
Blueprint Medicines's revenue has surged by 104% YoY and by 17% QoQ
Blueprint Medicines's equity has surged by 129% YoY but it has decreased by 4.6% QoQ
BPMC's debt is up by 41% year-on-year
BPMC's quick ratio is down by 24% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of BPMC
Market
Valuations
Earnings
Shares outstanding
63.91M
Market cap
$5.22B
Enterprise value
$5.58B
Price to earnings (P/E)
N/A
Price to book (P/B)
17.37
Price to sales (P/S)
10.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.96
Revenue
$508.82M
Gross profit
$488.66M
Operating income
-$212.04M
Net income
-$67.09M
EBIT
-$37.71M
EBITDA
-$11.5M
Free cash flow
-$197.22M
Per share
Balance sheet
Liquidity
EPS
-$1.07
EPS diluted
-$1.07
Free cash flow per share
-$3.14
Book value per share
$4.7
Revenue per share
$8.09
TBVPS
$18.77
Total assets
$1.18B
Total liabilities
$881.15M
Debt
$469.11M
Equity
$298.67M
Working capital
$481.88M
Debt to equity
1.57
Current ratio
2.85
Quick ratio
2.7
Net debt/EBITDA
-30.92
Margins
Efficiency
Dividend
EBITDA margin
-2.3%
Gross margin
96%
Net margin
-13.2%
Operating margin
-41.7%
Return on assets
-5.8%
Return on equity
-21.6%
Return on invested capital
-3%
Return on capital employed
-4.1%
Return on sales
-7.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BPMC stock price
How has the Blueprint Medicines stock price performed over time
Intraday
-6.23%
1 week
-7.94%
1 month
-8.61%
1 year
-9.93%
YTD
-6.35%
QTD
-7.72%
Financial performance
How have Blueprint Medicines's revenue and profit performed over time
Revenue
$508.82M
Gross profit
$488.66M
Operating income
-$212.04M
Net income
-$67.09M
Gross margin
96%
Net margin
-13.2%
BPMC's gross profit has surged by 107% year-on-year and by 16% since the previous quarter
Blueprint Medicines's revenue has surged by 104% YoY and by 17% QoQ
BPMC's net margin has soared by 94% year-on-year and by 55% since the previous quarter
The net income has soared by 87% YoY and by 48% QoQ
Growth
What is Blueprint Medicines's growth rate over time
Valuation
What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
17.37
P/S
10.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.96
Blueprint Medicines's EPS has surged by 87% YoY and by 48% QoQ
Blueprint Medicines's equity has surged by 129% YoY but it has decreased by 4.6% QoQ
The price to book (P/B) is 59% higher than the 5-year quarterly average of 10.9 but 10% lower than the last 4 quarters average of 19.3
Blueprint Medicines's revenue has surged by 104% YoY and by 17% QoQ
The P/S is 47% below the 5-year quarterly average of 19.1 and 37% below the last 4 quarters average of 15.9
Efficiency
How efficient is Blueprint Medicines business performance
Blueprint Medicines's return on sales has surged by 96% YoY and by 69% QoQ
The ROIC has soared by 93% YoY and by 65% from the previous quarter
BPMC's return on equity has surged by 89% year-on-year and by 55% since the previous quarter
The company's return on assets has surged by 87% YoY and by 49% QoQ
Dividends
What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BPMC.
Financial health
How did Blueprint Medicines financials performed over time
BPMC's total assets is 34% greater than its total liabilities
Blueprint Medicines's current ratio has decreased by 24% YoY and by 14% from the previous quarter
BPMC's quick ratio is down by 24% year-on-year and by 14% since the previous quarter
BPMC's debt is 57% greater than its equity
Blueprint Medicines's equity has surged by 129% YoY but it has decreased by 4.6% QoQ
BPMC's debt is up by 41% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.